CHMP backs basket of therapies

EMA's CHMP recommended marketing authorization of three new medicines Thursday and recommended label expansions for Revlimid lenalidomide from Celgene Corp. (NASDAQ:CELG) and Revolade eltrombopag from Novartis

Read the full 263 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE